Nesiritide vs Placebo: All-Cause Mortality Through Day 30
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.036 | 0.0303 | 0.0427 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0402 | 0.0342 | 0.0472 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.00416 | -0.0132 | 0.00484 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.896 | 0.708 | 1.13 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.893 | 0.699 | 1.14 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with the outcome on Nesiritide than on Placebo | 240 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Nesiritide | 0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs | 126 | 3,498 | OG000 | ClinicalTrials.gov |
| Group 2 | Placebo | Matching placebo infusion 0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs | 141 | 3,509 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | OTHER_PRE_SPECIFIED | ClinicalTrials.gov |
| Title | All-Cause Mortality Through Day 30 | ClinicalTrials.gov |
| Description | All deaths were adjudicated by an independent Clinical Events Committee. | ClinicalTrials.gov |
| Time frame | Randomization to Day 30 | ClinicalTrials.gov |
| Population | The safety population consisted of all randomized patients who received any amount of study medication. For all safety analyses, patients were analyzed according to the treatment actually received. 66 and 68 patients in the nesiritide and placebo groups, respectively, were not included in the safety population. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure | ClinicalTrials.gov |
| NCT number | NCT00475852 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | Heart Decompensation | ClinicalTrials.gov |
| Interventions | Nesiritide, Placebo | ClinicalTrials.gov |
| Lead sponsor | Scios, Inc. | ClinicalTrials.gov |
| Results first posted | 2012-05-10 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT00475852?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.